Detalles de la búsqueda
1.
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
Clin Infect Dis
; 76(4): 674-682, 2023 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35906831
2.
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
J Antimicrob Chemother
; 72(12): 3406-3413, 2017 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28961714
3.
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
J Antimicrob Chemother
; 72(12): 3501, 2017 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29029280
4.
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
J Acquir Immune Defic Syndr
; 91(1): 68-72, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35972855
5.
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial.
J Acquir Immune Defic Syndr
; 78(5): 589-598, 2018 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29771789
6.
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
J Acquir Immune Defic Syndr
; 82(4): e47-e49, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31425317
Resultados
1 -
6
de 6
1
Próxima >
>>